|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8829195||NOVARTIS||Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1|| |
(9 years from now)
|US11407735||NOVARTIS||Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide|| |
(16 years from now)
Scemblix is owned by Novartis.
Scemblix contains Asciminib Hydrochloride.
Scemblix has a total of 2 drug patents out of which 0 drug patents have expired.
Scemblix was authorised for market use on 29 October, 2021.
Scemblix is available in tablet;oral dosage forms.
Scemblix can be used as treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml).
Drug patent challenges can be filed against Scemblix from 2025-10-29.
The generics of Scemblix are possible to be released after 14 May, 2040.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||Oct 29, 2026|
|Orphan Drug Exclusivity (ODE)||Oct 29, 2028|
NCE-1 date: 2025-10-29
Market Authorisation Date: 29 October, 2021
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic